Pulling SEC filings + quote and writing the call…

Organogenesis Holdings Inc.
Next earnings Aug 5, 2026 · consensus $-0.26 EPS, $55.3M rev
Last earnings -1.2% on 2026-05-07
Revenue grew 17.0% YoY.
Middling fundamentals offset by an attractive price (~135% below fair value) — worth a look on the value angle.
Sources: SEC EDGAR (CIK 0001661181, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:42:19 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Organogenesis Holdings Inc. shows $564M in FY2025 revenue (+17.0% YoY), a 6.6% net margin, and 12.3% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $467M | $451M | $433M | $482M | $564M |
| Gross profit | $353M | $346M | $327M | $366M | — |
| Operating income | $72.2M | $22.3M | $12.5M | -$1.28M | $44.7M |
| Net income | $94.2M | $15.5M | $4.95M | $861K | $37.0M |
| Diluted EPS | $0.70 | $0.12 | $0.04 | -$0.01 | $0.15 |
| Net margin | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1049 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
| 2026-03-09 | Leibowitz Arthur S Director | Buy | 5.00K @ $2.68 | $13.4K |
| 2026-03-09 | Driscoll Michael Joseph Director | Buy | 10.0K @ $2.67 | $26.7K |
| 2026-03-01 | Cavorsi Robert Vice President, Strategy | Tax | 700.00 @ $3.21 | $2.25K |
| 2026-02-18 | Freedman Lori Chief Admin. and Legal Officer | Award | 203K | |
| 2026-02-18 | Freedman Lori Chief Admin. and Legal Officer | Award | 42.8K | |
| 2026-02-18 | Freedman Lori Chief Admin. and Legal Officer | Tax | 14.3K @ $3.84 | $54.8K |
| 2026-02-18 | Cavorsi Robert Vice President, Strategy | Award | 93.8K | |
| 2026-02-18 | Cavorsi Robert Vice President, Strategy | Award | 16.3K | |
| 2026-02-18 | Cavorsi Robert Vice President, Strategy | Tax | 5.43K @ $3.84 | $20.9K |
| 2026-02-18 | Francisco David Chief Financial Officer | Award | 195K | |
| 2026-02-18 | Francisco David Chief Financial Officer | Award | 43.6K | |
| 2026-02-18 | Francisco David Chief Financial Officer | Tax | 14.5K @ $3.84 | $55.8K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.